Aditxt Inc
NASDAQ:ADTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Shubham Polyspin Ltd
BSE:542019
|
IN |
|
Golden Entertainment Inc
NASDAQ:GDEN
|
US |
Aditxt Inc
Research & Development
Aditxt Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Aditxt Inc
NASDAQ:ADTX
|
Research & Development
-$3.3m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-41%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
Aditxt Inc
Glance View
Aditxt, Inc. engages in the development of biotechnologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring. The company is headquartered in Richmond, Virginia and currently employs 58 full-time employees. The company went IPO on 2020-06-19. The firm is developing technologies focused on improving the health of the immune system through immune mapping and reprogramming. The Company’s immune mapping technologies are designed to provide a personalized comprehensive profile of the immune system. The Company’s Apoptotic DNA Immunotherapy (ADi) technology has two categories, the AditxtReprogramming therapeutic program, which includes ADi and the AditxtScore diagnostic technology. AditxtScore is designed to allow individuals to understand, manage and monitor their immune profiles in order to be informed about attacks on or by their immune system. AditxtScore also assists the medical community in anticipating immune responses and reactions to viruses, bacteria, allergens and transplanted organs. ADi is a nucleic acid-based technology that suppresses only those immune cells involved in the rejection of tissue and transplanted organ.
See Also
What is Aditxt Inc's Research & Development?
Research & Development
-3.3m
USD
Based on the financial report for Sep 30, 2025, Aditxt Inc's Research & Development amounts to -3.3m USD.
What is Aditxt Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-41%
Over the last year, the Research & Development growth was 77%. The average annual Research & Development growth rates for Aditxt Inc have been 17% over the past three years , -41% over the past five years .
